BioScience Health Innovations Reports $229,907 Net Loss in Q1 2026 Amid Revenue Decline

BioScience Health Innovations, Inc. reported a net loss of $229,907 for the first quarter of 2026, a significant decline from a net income of $426,798 during the same period in 2025. The company's revenue decreased to $750,946, down from $1,227,070 year-over-year. This decline is attributed to adjustments in sales channels, including a transition to a new Amazon distributor and a shift in marketing strategy. The company had anticipated a substantial order from a major co-brand customer, which was postponed to the second quarter, further impacting revenue.

In terms of operational expenses, BioScience Health Innovations saw an increase in general and administrative expenses, which rose to $625,809 from $433,561 in the previous year. Consulting fees also increased significantly, from $35,786 to $89,694, as the company pursued a move from the Over-the-Counter market to a senior exchange. Despite the loss, the company reported accumulated earnings of $71,100 and a cash balance of $1,145,005 as of March 31, 2026, which management believes is sufficient to meet its obligations over the next year.

The company’s total assets increased to $2,330,239 from $1,707,181 at the end of 2025, driven by a rise in inventory and cash reserves. Inventory levels rose to $874,340, compared to $336,348 at the end of the previous year, reflecting the company's strategy to bolster its product offerings. Current liabilities also increased significantly, from $229,851 to $645,749, primarily due to a new note payable of $460,402 issued to related parties.

BioScience Health Innovations continues to focus on expanding its market presence, particularly in the mental health and wellness sectors. The company is actively pursuing a private placement to raise up to $1,000,000 to support its growth initiatives. Management is optimistic about the potential of its patent-pending Methylene Blue products and other specialty offerings, targeting various health conditions including cognitive decline and metabolic health. The company is also exploring strategic partnerships and acquisitions to enhance its market position.

Looking ahead, BioScience Health Innovations aims to leverage its innovative product lines and improve its operational efficiencies. The leadership team is committed to strengthening governance by adding independent directors in preparation for a potential Nasdaq uplist. The company remains focused on its growth strategy, with plans to enhance its fulfillment operations and expand its product offerings in the rapidly growing health and wellness market.